Clinical trials: Non-small Cell Lung Cancer Stage IV
Non-Small Cell Lung Cancer
A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash.
This 3 arm study will compare the efficacy and safety of three different dermatological creams designed for prophylaxis of skin rash associated with Tarceva treatment in patients with locally advanced or metastatic non-small cell…
- Trial name
- NCT00718315
- Testing
- erlotinib [Tarceva], fusidic acid [Verutex], erythromycin [Eritex]
- Where
- 26 sites in Brazil
- Volunteers
- 201 people
- Sponsor
- Hoffmann-La Roche
Lung Cancer
An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung Cancer
The purpose of this study is to evaluate the safety and tolerability of itacitinib in combination with osimertinib in subjects with locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Trial name
- NCT02917993
- Testing
- Itacitinib, Osimertinib
- Where
- 31 sites in United States, South Korea and 2 more
- Volunteers
- 59 people
- Sponsor
- Incyte Corporation
Non-small Cell Lung Cancer
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)
Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal.
- Trial name
- NCT06731907
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 41 sites in United States, Chile and 9 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer (NSCLC) Stage IV
A Study to Evaluate the Safety and Efficacy of Ex Vivo Expanded Autologous Immune Killer Cells (IKC) in Stage IV Non-small Cell Lung Cancer (NSCLC) in Patients Who Failed Chemotherapy or Target Therapy
In this study, whole blood is drawn from the patient to be used to grow Immune Killer Cells (IKC). After proliferation, the IKC will be infused back into the patient to treat the cancer for a total of 24 weekly treatments.
- Trial name
- IVY03 (NCT03499834)
- Testing
- Immune Killer Cells (IKC)
- Where
- 2 sites in Taiwan
- Volunteers
- 26 people
- Sponsor
- Ivy Life Sciences, Co., Ltd
Non-small Cell Lung Cancer
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
This study will compare overall survival in participants with Stage IIIB or IV nonsquamous non-small cell lung cancer.
- Trial name
- NCT00762034
- Testing
- Pemetrexed, Paclitaxel, Carboplatin
- Where
- 67 sites in United States
- Volunteers
- 939 people
- Sponsor
- Eli Lilly and Company
Lung Cancer Metastatic, NSCLC Stage IV
Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
This is an open-label, multi-center, single arm, phase II study to assess the anti-tumor activity and safety of bemcentinib in combination with pembrolizumab in up to 106 participants with previously treated, advanced…
- Conditions
- Lung Cancer Metastatic, NSCLC Stage IV, Adenocarcinoma of Lung
- Trial name
- NCT03184571
- Testing
- Pembrolizumab, Bemcentinib
- Where
- 13 sites in United States, Norway and 2 more
- Volunteers
- 99 people
- Sponsor
- BerGenBio ASA
Carcinoma, Non-Small-Cell Lung
Phase II Iressa & Carbo/Gem in NSCLC
The primary objective is to demonstrate in chemotherapy naïve patients with advanced (Stage IIIB or IV) NSCLC and ECOG PS 2 non-inferiority in progression free survival (PFS) for ZD1839 compared to gemcitabine/carboplatin.
- Trial name
- NCT00264498
- Testing
- Gefitinib, Gemcitabine, Carboplatin
- Where
- Canada
- Volunteers
- 38 people
- Sponsor
- AstraZeneca
Non-Small-Cell Lung Carcinoma
Phase IIB/III Of TG4010 Immunotherapy In Patients With Stage IV Non-Small Cell Lung Cancer
This is a Phase IIb/III randomized, double-blind, placebo-controlled study to compare the efficacy and safety of first-line therapy combined with TG4010 or placebo in stage IV non-small cell lung cancer (NSCLC).
- Trial name
- TIME (NCT01383148)
- Testing
- TG4010
- Where
- 72 sites in United States, Belgium and 8 more
- Volunteers
- 222 people
- Sponsor
- Transgene
Non Small Cell Lung Cancer
A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer
This is a Phase II, Open Label, Multicenter, Single Arm Study of WSD0922-FU for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer whose Disease has Progressed with First-Line Osimertinib Treatment and whose…
- Trial name
- NCT06868485
- Testing
- WSD0922-FU Tablets, Dose level A, WSD0922-FU Tablets, Dose level B
- Where
- 18 sites in United States, China and 1 more
- Volunteers
- 40 people
- Sponsor
- Wayshine Biopharm, Inc.
Lung Cancer
ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing.
- Trial name
- NCT00006049
- Testing
- carboplatin, gefitinib, paclitaxel
- Where
- United States
- Sponsor
- AstraZeneca
Carcinoma, Non Small Cell Lung
A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
The primary objective of the study was to demonstrate overall survival improvement for aflibercept + docetaxel compared to docetaxel + placebo as second line treatment for participants with locally advanced or metastatic…
- Trial name
- VITAL (NCT00532155)
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Docetaxel (Taxotere®), Dexamethasone (pre- and post-medication for docetaxel)
- Where
- 32 sites in United States, Argentina and 30 more
- Volunteers
- 913 people
- Sponsor
- Sanofi
Non Small Cell Lung Cancer
Multicentre Study to Explore the Correlation Between Smoking Pattern and Clinical Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Male Patients
The objective is to investigate the correlation between smoking pattern and clinical efficacy of EGFR TKIs in male patients with locally advanced or metastasized non-small cell lung cancer of adeno histology who have failed 1st…
- Trial name
- NCT00922025
- Where
- 6 sites in Taiwan
- Volunteers
- 186 people
- Sponsor
- AstraZeneca
Carcinoma, Non-Small-Cell Lung
A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer
Protocol AMP-024 is a Phase 2 study of imexon plus docetaxel for patients with previously treated lung cancer that has spread in the body.
- Trial name
- NCT00697060
- Testing
- Imexon + docetaxel
- Where
- 3 sites in United States
- Sponsor
- AmpliMed Corporation
Carcinoma, Non-Small-Cell Lung
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
The purpose of this study is to evaluate the safety and efficacy of Navlimetostat (BMS-986504) monotherapy or in combination with Izalontamab Brengitecan in participants with advanced or metastatic Non-small Cell Lung Cancer…
- Trial name
- NCT06855771
- Testing
- BMS-986504, Izalontamab Brengitecan
- Where
- 67 sites in United States, Australia and 10 more
- Volunteers
- 182 people
- Sponsor
- Bristol-Myers Squibb
Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are…
- Trial name
- NCT04613596
- Testing
- Adagrasib, Pembrolizumab
- Where
- 770 sites in United States, Argentina and 45 more
- Volunteers
- 626 people
- Sponsor
- Mirati Therapeutics Inc.
Lung Cancer
T138067 in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer That Has Not Responded to Previous Chemotherapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of T138067 in treating patients who have locally advanced…
- Trial name
- NCT00022243
- Testing
- batabulin sodium
- Where
- 2 sites in United States
- Sponsor
- Tularik
Carcinoma, Non-Small-Cell Lung
Study of DN101 and Taxotere in Patients With Advanced Non-Small Cell Lung Cancer
This Phase 1/2 clinical trial is a multi-center, open-label study with three main objectives. The first (Phase 1A) is to determine the maximum-tolerated dose of DN-101 when administered in combination with Taxotere (docetaxel)…
- Trial name
- NCT00066885
- Testing
- calcitriol + docetaxel
- Where
- 11 sites in United States
- Volunteers
- 80 people
- Sponsor
- Novacea